Effect of Daily Infusion Time of Immunotherapy on Overall Survival in NSCLC

Effect of Daily Infusion Time of Immunotherapy on Overall Survival in Patients With Advanced Non-small Cell Lung Cancer

Sponsors

Lead Sponsor: Hunan Province Tumor Hospital

Source Hunan Province Tumor Hospital
Brief Summary

This study aims to explore the effect of different infusion times (day or night) on the efficacy of immune checkpoint inhibitors on the basis of real-world efficacy of immunotherapy for advanced squamous/non-squamous non-small cell lung cancer.

Overall Status Recruiting
Start Date 2022-01-02
Completion Date 2023-12-31
Primary Completion Date 2023-12-02
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
ORR 1 year
OS 1 year
Enrollment 112
Condition
Intervention

Intervention Type: Procedure

Intervention Name: Time of immunotherapy infusion

Description: Time of immunotherapy infusion

Eligibility

Criteria:

Inclusion Criteria: - Patients with untreated non-small cell lung cancer - ECOG score 0-2 - Asymptomatic brain metastases - Driver gene was negative - At least 1 measurable lesion - First-line patients received immunological monotherapy or immunological combined chemotherapy Exclusion Criteria: - Failure to follow the standard treatment plan during diagnosis and treatment; - Lack of clinical diagnosis and treatment information or loss of follow-up; - Can't tolerate immunotherapy or ECOG score greater than 2

Gender:

All

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Yongchang Zhang, MD Principal Investigator Hunan Cancer Hospital
Overall Contact

Last Name: Yongchang C Zhang, MD

Phone: +8613873123436

Phone Ext.: 7+861383123436

Email: [email protected]

Location
Facility: Status: Contact: Contact Backup: Hunan Cancer Hospital Yongchang Zhang, MD +86 731 89762323 [email protected]
Location Countries

China

Verification Date

2022-09-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Hunan Province Tumor Hospital

Investigator Full Name: Yongchang Zhang

Investigator Title: Director, Head of Medical Oncology, Principal Investigator, Clinical Professor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: morning group

Type: Experimental

Description: The immunotherapy infusion is after 6:00 p.m

Label: afternoon group

Type: Experimental

Description: The immunotherapy infusion is after 6:00 p.m

Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Prevention

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-small Cell Lung Cancer

Clinical Trials on Time of immunotherapy infusion